Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neuroendocrine Tumors 6Carcinoma, Hepatocellular 2Carcinoid Tumor 2Serotonin Syndrome 1Peritoneal Neoplasms 1Neuroendocrine Tumour With Carcinoid Symptoms 1Neoplastic Cells, Circulating 1Neoplasms 1Intestinal Obstruction 1Gastro-enteropancreatic neuroendocrine tumor 1Flushing 1Endocrine Tumors 1Diarrhea 1Carcinoma, Merkel Cell 1Carcinoma 1Acromegaly 1

Interventions

Paclitaxel 16Carboplatin 14Cisplatin 12Oxaliplatin 9Hyperthermic Intraperitoneal Chemotherapy 9Cytoreduction Surgical Procedures 9Fluorouracil 7Bevacizumab 7Doxorubicin 5Leucovorin 4Gemcitabine 4catumaxomab 3Docetaxel 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3nintedanib 2liposomal doxorubicin 2epothilone B 2Surgical Procedures, Operative 2Palliative Care 2Mitomycin 2Laparoscopy 2Interviews as Topic 2Drug Therapy 2Blood Specimen Collection 2veliparib 1tremelimumab 1talimogene laherparepvec 1strattice 1sodium thiosulfate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Peritoneal Neoplasms × lanreotide × Clear all
NCT00216372 2020-11-05

Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis

Ipsen

Phase 3 Completed
80 enrolled
Gynecologic

Carcinoma, Intestinal Obstruction, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡